Literature DB >> 21651614

Vanishing clinical psychopharmacology.

Joop van Gerven, Adam Cohen.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21651614      PMCID： PMC3141181          DOI： 10.1111/j.1365-2125.2011.04021.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  15 in total

Review 1.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

2.  Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.

Authors:  L Zuurman; C Roy; R C Schoemaker; A Amatsaleh; L Guimaeres; J L Pinquier; A F Cohen; J M A van Gerven
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

Review 3.  Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis.

Authors:  Brisa Simões Fernandes; Clarissa Severino Gama; Keila Maria Ceresér; Lakshmi N Yatham; Gabriel Rodrigo Fries; Gabriela Colpo; David de Lucena; Mauricio Kunz; Fabiano Alves Gomes; Flavio Kapczinski
Journal:  J Psychiatr Res       Date:  2011-05-06       Impact factor: 4.791

4.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 5.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

Review 6.  Clinical trials in traumatic brain injury: lessons for the future.

Authors:  Egon M R Doppenberg; Sung C Choi; Ross Bullock
Journal:  J Neurosurg Anesthesiol       Date:  2004-01       Impact factor: 3.956

7.  SSRI treatment decreases prolactin and hyperthermic responses to mCPP.

Authors:  D J Quested; P A Sargent; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1997-10       Impact factor: 4.530

8.  Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.

Authors:  M Liem-Moolenaar; F A Gray; S J de Visser; K L Franson; R C Schoemaker; J A J Schmitt; A F Cohen; J M A van Gerven
Journal:  J Psychopharmacol       Date:  2008-08-28       Impact factor: 4.153

Review 9.  Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.

Authors:  John H Krystal; David F Tolin; Gerard Sanacora; Stacy A Castner; Graham V Williams; Deane E Aikins; Ralph E Hoffman; D Cyril D'Souza
Journal:  Drug Discov Today       Date:  2009-05-19       Impact factor: 7.851

10.  Alzheimer's disease therapeutic research: the path forward.

Authors:  Paul S Aisen
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982
View more
  11 in total

1.  Time for clinical trials of epigenetic drugs in psychiatric disorders?

Authors:  Jacob Peedicayil; Aniket Kumar
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 2.  From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?

Authors:  A Richard Green; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

3.  Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

4.  Drugs for Alzheimer's disease.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 5.  Epigenetic pharmacotherapy for substance use disorder.

Authors:  Gregory C Sartor
Journal:  Biochem Pharmacol       Date:  2019-07-12       Impact factor: 5.858

6.  Critical neuroscience-or critical science? A perspective on the perceived normative significance of neuroscience.

Authors:  Stephan Schleim
Journal:  Front Hum Neurosci       Date:  2014-05-20       Impact factor: 3.169

7.  How Realistic Are the Scientific Assumptions of the Neuroenhancement Debate? Assessing the Pharmacological Optimism and Neuroenhancement Prevalence Hypotheses.

Authors:  Stephan Schleim; Boris B Quednow
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

8.  Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Authors:  Eduardo Ekman Schenberg
Journal:  Front Pharmacol       Date:  2018-07-05       Impact factor: 5.810

9.  Whose well-being? Common conceptions and misconceptions in the enhancement debate.

Authors:  Stephan Schleim
Journal:  Front Syst Neurosci       Date:  2014-08-19

10.  Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.

Authors:  Elan A Cohen; Howard H Hassman; Larry Ereshefsky; David P Walling; Vera M Grindell; Richard S E Keefe; Katarzyna Wyka; William P Horan
Journal:  Neuropsychopharmacology       Date:  2020-11-26       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.